Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | USP2 | O75604 | 1/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.39 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.38 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.38 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.35 |
| ▸ | MTOR | P42345 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21798456 | 1.00 | ATM (0.45) | ATMTDP1L3MBTL1USP2ALOX15 | |
| SCHEMBL21798451 | 1.00 | ATM (0.45) | ATMTDP1L3MBTL1USP2ALOX15 | |
| SCHEMBL21798440 | 1.00 | ATM (0.45) | ATMTDP1L3MBTL1USP2ALOX15 | |
| SCHEMBL21798425 | 0.86 | ATM (0.44) | ATMTDP1L3MBTL1USP2ALOX15 | |
| SCHEMBL21798429 | 0.86 | ATM (0.44) | ATMTDP1L3MBTL1USP2ALOX15 | |
| SCHEMBL4226867 | 0.76 | ALOX15 (0.45) | ATMTDP1L3MBTL1USP2ALOX15 | |
| SCHEMBL960788 | 0.75 | ALOX5 (0.45) | ALDH1A1ALOX5TRPM8MTOR | |
| SCHEMBL28032109 | 0.75 | ALOX5 (0.47) | L3MBTL1KDM4EALDH1A1ALOX5TRPM8 | |
| SCHEMBL21798479 | 0.73 | CYP2C19 (0.41) | TDP1TSHRKDM4EALDH1A1ALOX5 | |
| SCHEMBL21798476 | 0.73 | CYP2C19 (0.41) | TDP1TSHRKDM4EALDH1A1ALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10738064-B2 | Chiral α-amino tertiary boronic esters | PURDUE RESEARCH FOUNDATION (US) | 2020-08-11 | — | — | US | disclosed |
| US-20200079799-A1 | Novel Chiral Alfa-Amino Tertiary Boronic Esters | PURDUE RESEARCH FOUNDATION (US) | 2020-03-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200079799-A1 | Novel Chiral Alfa-Amino Tertiary Boronic Esters | HBB, BCAT1, BCAT2 | ATM 4330/4885TDP1 4714/4885L3MBTL1 883/4885 |
| US-10738064-B2 | Chiral α-amino tertiary boronic esters | HBB, BCAT1, BCAT2 | ATM 3960/4885TDP1 4537/4885L3MBTL1 690/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.